title: [Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation Using Tumor-ablative Conditioning Regimen for Patients with Refractory/Relapsed Non-Hodgkin's Lymphoma].
abstract: OBJECTIVE
  To investigate the safety and effectiveness of autologous hematopoietic stem cell transplantation (auto-HSCT) using tumor-ablative conditioning regiment for patients with refractory/relapsed non-Hodgkin's lymphoma.
  
  
  METHODS
  The clinical data of 16 patients with refractory/relapsed non-Hodgkin's lymphoma received above-mentioned therapeutic regimen from January 2013 to July 2015 was analyzed retrospectively, and conditioning-related toxicity, engraftment, infection, relapse and survival rate were evaluated.
  
  
  RESULTS
  No conditioning-related organs' failure and mortality were found. Only 1 patient had not been engrafted, and the engraftment rate was 93.7%. The incidence of serious infection was 31.2%. The median follow-up was 20.5(1-30) months, and 3 patients died, out of them 2 patients died of relapse. Two year overall survival (OS) , disease-free survival (DFS) and relapse rates were 80.2%, 74.5% and 20.6% respectively.
  
  
  CONCLUSIONS
  Auto-HSCT using tumor-ablative conditioning regimen is safe and effective for patients with refractory/relapsed non-Hodgkin's lymphoma, and it possess a certain effect for reducing disease relapse after transplantation.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Xue-Liang
authors.initials: XL
authors.lastname: Yang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Ya-Mei
authors.initials: YM
authors.lastname: Wu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Yong-Bin
authors.initials: YB
authors.lastname: Cao
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Li
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Xu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Zhou-Yang
authors.initials: ZY
authors.lastname: Liu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Bei
authors.initials: B
authors.lastname: Liu
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Bei
authors.initials: B
authors.lastname: Yan
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors.forename: Song-Wei
authors.initials: SW
authors.lastname: Li
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Wan-Ming
authors.initials: WM
authors.lastname: DA
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China. E-mail: xiongwuxiao@sohu.com.
authors.forename: Xiao-Xiong
authors.initials: XX
authors.lastname: Wu
mesh_terms: D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome